-
Mashup Score: 0
Dr. Cytryn provides insights on the FDA approval of zolbetuximab and how it will impact clinical practice.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 0
Dr. Cytryn provides insights on the FDA approval of zolbetuximab and how it will impact clinical practice.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
👉 We spoke with Dr. @Sam_Cytryn of @MSKCancerCenter on the impact of #zolbetuximab for first-line treatment of advanced gastric and gastroesophageal junction cancers. 📺 Hear his further comments on the results of the GLOW and SPOTLIGHT trials: https://t.co/M6fhOwoBPn https://t.co/SS31c7hyfd
-
-
Mashup Score: 0
Dr. Cytryn provides insights on the FDA approval of zolbetuximab and how it will impact clinical practice.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
👉 We spoke with Dr. @Sam_Cytryn of @MSKCancerCenter on the impact of #zolbetuximab for first-line treatment of advanced gastric and gastroesophageal junction cancers. 📺 Hear his further comments on the results of the GLOW and SPOTLIGHT trials: https://t.co/M6fhOwoBPn https://t.co/SS31c7hyfd
-
-
Mashup Score: 0
Home > Gastric Cancer > Pranob Bhattacharya Discusses a Potential New Treatment Option for Gastric Cancer Astellas Pharma US, Inc. recently announced that the European Medicines Agency has accepted the Marketing Authorization Application (MAA) for regulatory review of zolbetuximab, a first-in-class investigational Claudin 18.2 (CLDN18.2)-targeted monoclonal antibody, for the potential first-line treatment of patients with locally adv anced unresectable or metastatic HER2-negative gastric or gastroesophageal
Source: www.docwirenews.comCategories: Latest Headlines, Partners & KOLsTweet-
Pranob Bhattacharya, Executive Director, Gastrointestinal Cancer Global Brand Lead, @AstellasUS, talks about the dangers of gastric cancer, and how zolbetuximab may effectively treat the malignancy. https://t.co/r84q5uMS9r #gastriccancer #gioncology #zolbetuximab https://t.co/zUceJ6Rn2h
-
-
Mashup Score: 0Zolbetuximab regimen extends survival in gastric, gastroesophageal junction cancer subset - 2 year(s) ago
The addition of zolbetuximab to capecitabine and oxaliplatin significantly extended PFS and OS for patients with claudin-18.2-positive/HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction cancer.The results of the phase 3 GLOW study, presented during an ASCO Plenary Series session, align with those of the phase 3 SPOTLIGHT trial, which evaluated the
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Zolbetuximab regimen extends survival in gastric, gastroesophageal junction cancer subset. https://t.co/kbzODeeZqL #Zolbetuximab @WeillCornell @AstellasUS @MSKCancerCenter #HemOnc #OncAlert #MedEd
-
-
Mashup Score: 0Zolbetuximab/CAPOX Prolongs Survival in CLDN18.2-Positive/HER2-Negative Advanced Gastric/GEJ Cancers - 2 year(s) ago
FDA approval may be looming for the combination of zolbetuximab and capecitabine/oxaliplatin after primary phase 3 results were presented during the March ASCO Virtual Plenary.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Zolbetuximab + #CAPOX showed a statistically significant and clinically meaningful PFS and OS prolongation in patients with unresectable or metastatic gastric or GEJ adenocarcinoma. #gicsm | @mdmanishshah @WeillCornell @ASCO #GI23 #oncology https://t.co/bp1eNJbYmi
-
-
Mashup Score: 13ASCO Plenary Series Program - 2 year(s) ago
Learn more about the faculty and program for the March Plenary Series session.
Source: ASCOCategories: Hem/Oncs, Latest HeadlinesTweet-
🆕 @ASCO #ASCOPlenarySeries @mdmanishshah @WeillCornell GLOW🕯️trial #Zolbetuximab+Chemo in #Claudin-18.2➕(🎯CLDN18.2+) advanced/metastatic gastric or gastroesophageal junction adenocarcinoma ✅One more actionable target. #STCSM #ESOCSM https://t.co/lpOomDpaBP @OncoAlert https://t.co/8mfjC02zco
-
-
Mashup Score: 0
Samuel Klempner, MD, explains the rationale for the phase 3 SPOTLIGHT study.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Samuel Klempner, MD, explains the rationale for the phase 3 SPOTLIGHT study of #zolbetuximab administered with #mFOLFOX6 vs with placebo plus mFOLFOX6. #gicsm | @MGHCancerCenter @KlempnerSam https://t.co/BTEDCHzxk6
-
-
Mashup Score: 0Zolbetuximab benefits subset of patients with gastric, gastroesophageal junction cancer - 2 year(s) ago
First-line treatment with zolbetuximab added to chemotherapy significantly extended OS and PFS among adults with certain forms of claudin-18.2-positive/HER2-negative gastric adenocarcinoma, results of the phase 3 SPOTLIGHT trial showed.Study participants, who had locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, demonstrated a 25% reduction in risk
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Zolbetuximab benefits subset of patients with gastric, gastroesophageal junction cancer. https://t.co/f6oZybULVQ #GastroesophagealJunctionCancer #zolbetuximab #GastricAdenocarcinoma @AstellasUS
-
-
Mashup Score: 0
The combination of zolbetuximab and mFOLFOX6 prolonged survival in patients with CLDN18.2+ advanced gastric gastroesophageal junction adenocarcinoma, according to the phase 3 data from the SPOTLIGHT trial.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
SPOTLIGHT trial of #zolbetuximab + mFOLFOX6 improved progression-free and overall survival in patients with CLDN18.2+, HER2- locally advanced unresectable or metastatic gastric/#GEJ adenocarcinoma. #gicsm #GI23 | @KoheiShitara https://t.co/71hfauDro7
-
👉 We spoke with Dr. @Sam_Cytryn of @MSKCancerCenter on the impact of #zolbetuximab for first-line treatment of advanced gastric and gastroesophageal junction cancers. 📺 Hear his further comments on the results of the GLOW and SPOTLIGHT trials: https://t.co/M6fhOwoBPn https://t.co/SS31c7hyfd